Bianchetti M G, Beretta-Piccoli C, Weidmann P, Link L, Boehringer K, Ferrier C, Morton J J
Hypertension. 1983 Jul-Aug;5(4 Pt 2):II57-65. doi: 10.1161/01.hyp.5.4_pt_2.ii57.
To elucidate the mechanisms involved in calcium-mediated blood pressure (BP) control, plasma norepinephrine (NE), epinephrine, renin activity, and angiotensin II (AII) levels and the cardiovascular pressor responsiveness to NE and AII were assessed before and during acute mild hypercalcemia or short-term calcium (Ca) inhibition with nifedipine in 20 normal and five borderline hypertensive subjects. In normal subjects, systolic BP and plasma NE and epinephrine concentrations were increased significantly (p less than 0.05) during an acute rise in serum Ca of 3.1 mg/dl (intermediate rate Ca infusion, 0.05 mg/kg/min for 3 hours), but not following an increase of 1 mg/dl (low rate Ca infusion, 0.034 mg/kg/min for 2 hours). In the borderline hypertensive group, low-rate Ca infusion elevating serum Ca by 1 mg/dl was associated with a slight increase in systolic BP (p less than 0.05) and plasma catecholamines. In both groups, the pressor responses to infused NE and AII, and plasma renin and AII levels, were unchanged during mild to moderate hypercalcemia. Nifedipine given for 2 weeks (average dose, 48 mg/d) reduced BP significantly (p less than 0.05) in the borderline hypertensive subjects only and NE pressor responses in both groups (p less than 0.025), but had no significant effect on plasma catecholamines, renin, or AII levels. These findings suggest that the adrenergic BP control mechanism may be more dependent on clinical variations in calcium metabolism than the angiotensin BP regulatory mechanism. Acute hypercalcemia may increase BP at least in part by causing an increase in adrenergic activity without an equivalent decrease in cardiovascular reactivity. Calcium inhibition with nifedipine may modify noradrenergic BP control by lowering the NE pressor reactivity without causing an equivalent increase in adrenergic activity.
为阐明钙介导的血压(BP)调控机制,在20名正常人和5名临界高血压患者中,评估了急性轻度高钙血症期间及用硝苯地平进行短期钙(Ca)抑制前后的血浆去甲肾上腺素(NE)、肾上腺素、肾素活性、血管紧张素II(AII)水平,以及心血管系统对NE和AII的升压反应。在正常受试者中,血清钙急性升高3.1mg/dl(中等速率钙输注,0.05mg/kg/min,持续3小时)期间,收缩压、血浆NE和肾上腺素浓度显著升高(p<0.05),但血清钙升高1mg/dl(低速率钙输注,0.034mg/kg/min,持续2小时)后则无此变化。在临界高血压组中,低速率钙输注使血清钙升高1mg/dl与收缩压和血浆儿茶酚胺轻度升高相关(p<0.05)。在两组中,轻度至中度高钙血症期间,对输注的NE和AII的升压反应以及血浆肾素和AII水平均未改变。仅在临界高血压受试者中,给予硝苯地平2周(平均剂量,48mg/d)可显著降低血压(p<0.05),并降低两组中NE的升压反应(p<0.025),但对血浆儿茶酚胺、肾素或AII水平无显著影响。这些发现提示,肾上腺素能血压调控机制可能比血管紧张素血压调节机制更依赖于钙代谢的临床变化。急性高钙血症可能至少部分通过引起肾上腺素能活性增加而不伴有心血管反应性等量降低来升高血压。用硝苯地平抑制钙可能通过降低NE升压反应性而不引起肾上腺素能活性等量增加来改变去甲肾上腺素能血压调控。